Lifeboat Foundation

Novak Djokovic, age 35, sometimes hangs out in a pressurized egg to enrich his blood with oxygen and gives pep talks to glasses of water, hoping to purify them with positive thinking before he drinks them. Tom Brady, 45, evangelizes supposedly age-defying supplements, hydration powders and pliability spheres. LeBron James, 38, is said to spend $1.5 million a year on his body to keep Father Time at bay. While most of their contemporaries have retired, all three of these elite athletes remain marvels of fitness. But in the field of modern health science, they’re amateurs compared to Bryan Johnson.

Middle-aged tech centimillionaire Bryan Johnson and his team of 30 doctors say they have a plan to reboot his body.

We spoke with Dr Morgan Levine 2 years ago concerning the remarkable results that she and a team that included Dr David Sinclair had in restoring vision in mice. In that experiment, published in the journal Nature, older mice had tighter optic nerves crushed causing blindness. Then, using a combination of 3 of the 4 Yamanaka cellular programing factors, they were able to restore the mice’s vision by signally the underlying DNA, rebuilding what had been thought to be permanently damaged cells. This was a remarkable result, as it was restoring a damaged organ, essentially a part of the brain, to its original healthy state. When I spoke to Dr Levine about the next step in her research, she mentioned it may be a more complex organ, such as a mouse liver.

But they went further. In the January issue of Cell, Sinclair published results of their ability to age an entire mouse. That is, to signal the epigenome to cause the underlying mouse DNA to behave as if it were much older. They were also able to do the reverse: to take an older mouse and, by signaling the epigenome, bring its cells and organs to the state of a younger mouse. This is a truly remarkable achievement, and it seems to prove Sinclair’s theory that all of our cells have within them a pristine copy of their DNA, and that aging and the disease associated with aging are the result of miscues from the epigenome. If these miscues can be corrected then the cell can be restored, not to a blank stem cell but to its original condition.

I guess we will have more medicine delivered through the nose in the future.

Antibody molecules sprayed into the noses of rats have led to the repair of stroke-like damage in the brain, and it may be because the drugs travelled through nerve cells for smell.

Perceptually-enabled Task Guidance prototypes demonstrated ability to help people complete recipes as a proxy to unfamiliar tasks.

“Perceptually-enabled Task Guidance (PTG) teams demonstrated a recipe for success in early prototypes of super smart #AIassistants that can see what a user sees and hear what they hear to help them accomplish unfamiliar tasks. More: https://www.darpa.mil/news-events/2023-01-25”

@AuroraFlightSci will design a full-scale X-plane that relies solely on changes in air flow for in-flight maneuvers. #ActiveFlowControl #XPlane More: https://www.darpa.mil/news-events/2023-01-17

Baykar is moving forward in Kızılelma Unmanned Combat Aerial Vehicle (UCAV) programme. The first prototype of the aircraft has completed the second flight from facilities based at Çorlu Atatürk Airport without issue.

More: https://www.darpa.mil/news-events/2023-01-24

Mistletoe may be a welcome holiday sight when hung over a doorway if a loved one is near. But it can be an unwelcome intruder when found in your trees, according to a Texas A&M AgriLife Extension Service horticulturist.

“Mistletoe is a hemiparasite—a semi-parasitic plant,” said Allison Watkins, AgriLife Extension horticulturist for Tom Green County. “It makes its food from photosynthesis, but the roots grow into the host tree, sucking water and minerals out from the sap.”

In other words, you likely do not want to see mistletoe growing on your favorite shade tree or prized ornamental. However, mistletoe can survive as long as the tree it inhabits. So, some mistletoe alive today may still be around in 100 years.

You’ve seen the headlines. The FDA approved its use in tackling the underlying genetic mutation for sickle cell disease. Some researchers edited immune cells to fight untreatable blood cancers in children. Others took pig-to-human organ transplants from dream to reality in an attempt to alleviate the shortage of donor organs. Recent work aims to help millions of people with high cholesterol—and potentially bring CRISPR-based gene therapy to the masses—by lowering their chances of heart disease with a single injection.

But to Dr. Jennifer Doudna, who won the Nobel Prize in 2020 for her role in developing CRISPR, we’re just scratching the surface of its potential. Together with graduate student Joy Wang, Doudna laid out a roadmap for the technology’s next decade in an article in Science.

If the 2010s were focused on establishing the CRISPR toolbox and proving its effectiveness, this decade is when the technology reaches its full potential. From CRISPR-based therapies and large-scale screens for disease diagnostics to engineering high-yield crops and nutritious foods, the technology “and its potential impact are still in their early stages,” the authors wrote.